Compare FLWS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | VYGR |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.0M | 222.4M |
| IPO Year | 1999 | 2015 |
| Metric | FLWS | VYGR |
|---|---|---|
| Price | $4.07 | $3.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.50 | ★ $17.00 |
| AVG Volume (30 Days) | 683.7K | ★ 745.6K |
| Earning Date | 01-29-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,585,455,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.93 | $2.65 |
| 52 Week High | $9.12 | $5.73 |
| Indicator | FLWS | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 42.84 |
| Support Level | $3.80 | $3.51 |
| Resistance Level | $4.25 | $4.09 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 21.69 | 29.37 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.